Law firm investigates GeneDx after shares plunge 50% on weak earnings and lowered guidance

Bragar Eagel & Squire, P.C. is investigating GeneDx Holdings Corp. following the company's Q1 2026 report showing a $57.5 million loss and a 50% drop in share price. GeneDx lowered its 2026 revenue forecast by $65 million due to weaker reimbursement rates and poor performance in noncore business lines. The firm is exploring potential securities law violations and encourages affected investors to contact them for legal options.